- Home
- BIIB vs PTC Comparison
BIIB vs PTC Comparison
Compare BIIB & PTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- PTC
- Stock Information
- Founded
- BIIB 1978
- PTC 1985
- Country
- BIIB United States
- PTC United States
- Employees
- BIIB 7605
- PTC N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- PTC Computer Software: Prepackaged Software
- Sector
- BIIB Health Care
- PTC Technology
- Exchange
- BIIB Nasdaq
- PTC Nasdaq
- Market Cap
- BIIB 20.6B
- PTC 22.2B
- IPO Year
- BIIB 1991
- PTC 1989
- Fundamental
- Price
- BIIB $140.60
- PTC $161.65
- Analyst Decision
- BIIB Buy
- PTC Buy
- Analyst Count
- BIIB 27
- PTC 11
- Target Price
- BIIB $220.50
- PTC $211.00
- AVG Volume (30 Days)
- BIIB 1.5M
- PTC 1.4M
- Earning Date
- BIIB 02-12-2025
- PTC 02-05-2025
- Dividend Yield
- BIIB N/A
- PTC N/A
- EPS Growth
- BIIB 40.28
- PTC 63.98
- EPS
- BIIB 11.18
- PTC 3.25
- Revenue
- BIIB $9,675,900,000.00
- PTC $2,313,386,000.00
- Revenue This Year
- BIIB N/A
- PTC $11.33
- Revenue Next Year
- BIIB $1.57
- PTC $10.12
- P/E Ratio
- BIIB $12.65
- PTC $49.75
- Revenue Growth
- BIIB N/A
- PTC 6.05
- 52 Week Low
- BIIB $128.51
- PTC $161.02
- 52 Week High
- BIIB $238.00
- PTC $203.09
- Technical
- Relative Strength Index (RSI)
- BIIB 44.88
- PTC 24.54
- Support Level
- BIIB $135.02
- PTC $164.68
- Resistance Level
- BIIB $141.69
- PTC $172.09
- Average True Range (ATR)
- BIIB 4.00
- PTC 5.02
- MACD
- BIIB 0.04
- PTC -1.30
- Stochastic Oscillator
- BIIB 59.44
- PTC 1.94
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About PTC PTC Inc.
PTC offers high-end computer-assisted design (Creo) and product lifecycle management (Windchill) software as well as Internet of Things and AR industrial solutions. Founded in 1985, PTC has 28,000 customers, with revenue stemming mostly from North America (45%) and Europe (40%).